Abstract:Sepsis and acute kidney injury (AKI) are two major public health concerns that contribute significantly to illness and death worldwide. Early diagnosis and prompt treatment are essential for achieving the best possible outcomes. To date, there are no specific clinical, imaging, or biochemical indicators available to diagnose sepsis, and diagnosis of AKI based on the KDIGO criterion has limitations. To improve the diagnostic process for sepsis and AKI, it is essential to continually evolve our understanding of these conditions. Delays in diagnosis and appropriate treatment can have serious consequences. Sepsis and AKI often occur together, and patients with kidney dysfunction are more prone to developing sepsis. Therefore, identifying potential biomarkers for both conditions is crucial. In this review, we talk about the main biomarkers that evolve the diagnostic of sepsis and AKI, namely neutrophil gelatinase-associated lipocalin (NGAL), proenkephalin (PENK), and cell-free DNA.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to explore the role of biomarkers in the diagnosis of sepsis and acute kidney injury (AKI). Specifically, the paper attempts to solve the following key problems: 1. **Challenges in early diagnosis**: - Early diagnosis of sepsis and AKI is crucial for improving patient prognosis. However, there is currently a lack of specific clinical, imaging, or biochemical indicators for the early diagnosis of these two diseases. - Traditional diagnostic methods have limitations. For example, AKI diagnosis based on the KDIGO criteria is usually late and cannot provide information about the cause, type, and severity. 2. **Potential value of biomarkers**: - Identify and validate biomarkers that can diagnose sepsis and AKI early to improve the accuracy and timeliness of diagnosis. - Explore the applications of several major biomarkers, such as neutrophil gelatinase - associated lipocalin (NGAL), proenkephalin (PENK), and cell - free DNA (cfDNA), in the diagnosis of sepsis and AKI. 3. **Specific mechanisms of biomarkers**: - Describe the physiological and pathological mechanisms of these biomarkers in sepsis and AKI and how they reflect the progress of the disease. - Analyze the performance of these biomarkers in different clinical situations, such as pediatric and adult cardiac surgery, critically ill patients, kidney transplantation, and the emergency room. 4. **Prospects for clinical applications**: - Explore the potential applications of these biomarkers in clinical practice, including early diagnosis, risk stratification, treatment response assessment, and prognosis prediction. - Discuss how the comprehensive use of these biomarkers in sepsis and AKI can improve the accuracy of diagnosis, especially under highly heterogeneous conditions. ### Main conclusions - **NGAL**: As a major diagnostic biomarker for AKI and sepsis, NGAL has shown high sensitivity and specificity in multiple clinical studies. Changes in its expression in renal tubular epithelial cells and neutrophils can reflect kidney injury and neutrophil activation. - **PENK**: It acts through the delta - opioid receptor in the kidney and is closely related to the progression of renal insufficiency and AKI. In sepsis, PENK is involved in regulating the inflammatory response. - **cfDNA**: Extracellular DNA released by the massive death of immune cells caused by infection is involved in the host immune response and the development of multiple organ dysfunction syndrome (MODS). Through the study of these biomarkers, the paper aims to provide new ideas and tools for the early diagnosis and management of sepsis and AKI.

The Role of Biomarkers in Diagnosis of Sepsis and Acute Kidney Injury

Biomarkers, Diagnosis and Management of Sepsis-Induced Acute Kidney Injury: a Narrative Review.

Biomarkers for Early Diagnosis of Acute Kidney Injury: Current Progress and Clinical prospects.

Novel Damage Biomarkers of Sepsis-Related Acute Kidney Injury

Biomarkers of Acute Kidney Injury after Cardiac Surgery: A Narrative Review

The role of biomarkers in early identification of acute kidney injury among non-critically ill patients

[Advances in the clinical value of tissue inhibitors of metalloproteinase-2 and insulin-like growth factor binding protein 7 in sepsis associated-acute kidney injury].

Improving acute kidney injury diagnostic precision using biomarkers

Serum cystatin C, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, klotho and fibroblast growth factor-23 in the early prediction of acute kidney injury associated with sepsis in a Chinese emergency cohort study

Sepsis-Associated Acute Kidney Injury: Where Are We Now?

The diagnostic and prognostic values of serum and urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin in sepsis induced acute renal injury patients

Identification of Biomarkers for the Diagnosis of Sepsis-Associated Acute Kidney Injury and Prediction of Renal Recovery in the Intensive Care Unit

New Biomarkers in Early Diagnosis of Acute Kidney Injury in Children

Acute Kidney Injury in Sepsis

Biomarkers vs Machines: The Race to Predict Acute Kidney Injury

Gene Expression Profiling of Sepsis-Associated Acute Kidney Injury

The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice

Acute Kidney Injury and Sepsis after Cardiac Surgery: The Roles of Tissue Inhibitor Metalloproteinase-2, Insulin-like Growth Factor Binding Protein-7, and Mid-Regional Pro-Adrenomedullin

Serum Interleukin-18, Kidney Injury Molecule-1, and the Renal Resistive Index for Predicating Acute Kidney Injury in Critically Ill Patients with Sepsis.

Renal arterial resistive index versus novel biomarkers for the early prediction of sepsis-associated acute kidney injury

Acute Kidney Injury: Epidemiology, Diagnosis, Prognosis, and Future Directions